Cortical excitability in very mild Alzheimer's disease: a long-term follow-up study

J Olazarán1, J Prieto, I Cruz

  • 1Neurology Service, Gregorio Marañón General University Hospital, Madrid, Spain. javier@mariawolff.es

Journal of Neurology
|August 4, 2010
PubMed

Insights

Paired-pulse transcranial magnetic stimulation (pTMS) showed reduced motor cortex excitability in Alzheimer's disease (AD) patients. While not ideal for early AD diagnosis, pTMS may help predict treatment response and understand disease mechanisms.

Area of Science:

  • Neuroscience
  • Neurology
  • Cognitive Science

Background:

  • Paired-pulse transcranial magnetic stimulation (pTMS) is a potential tool for assessing motor cortex excitability.
  • Early diagnosis and monitoring of Alzheimer's disease (AD) progression and treatment response are critical.
  • Limited research exists on pre-dementia stages, long-term data, and cognitive correlations of cortical excitability in AD.

Purpose of the Study:

  • To investigate motor cortex excitability using pTMS in individuals with mild cognitive impairment (MCI) who later developed AD.
  • To assess changes in cortical excitability over time and in response to donepezil treatment.
  • To explore the relationship between cortical excitability and cognitive performance in the context of AD.

Main Methods:

  • Recruited eleven MCI patients who converted to AD and 12 elderly controls.
  • Conducted cognitive assessments and pTMS at baseline, and at 4 and 21 months for the AD group.
  • Utilized non-parametric statistics for group comparisons and correlation analysis between excitability and cognition.

Main Results:

  • Reduced short-latency intracortical inhibition (SICI) and intracortical facilitation were observed in AD patients, particularly at a 2-ms interstimulus interval (ISI).
  • A trend towards SICI recovery was noted after donepezil treatment.
  • Baseline cortical excitability at 300 ms correlated with better cognitive performance in AD patients.

Conclusions:

  • pTMS may not be suitable for the early diagnosis of late-onset AD due to high inter-individual variability.
  • pTMS shows potential for predicting treatment response in AD.
  • Cortical excitability measures could offer insights into AD disease mechanisms and progression.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.